Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Ketamine for Non-suicidal Self-injuries in Women with cPTSD
NCT04242914Phase 2Unknown
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Feb 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ketamine in nonsuicidal self-injury (NSSI) and complex post-traumatic stress disorder (cPTSD) (2 arms), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoint: Clinical measures - non suicidal self injuries symptoms. Status: unknown.
02
Drugs
ketamine
03
Conditions
nonsuicidal self-injury (NSSI)complex post-traumatic stress disorder (cPTSD)
Beyond the preview
Go deeper on NCT04242914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04242914.